Electron Microscopic Study of Cell Lines Established from Adult T-Cell Leukemia--Coexistence of Adult T-Cell Leukemia Virus and Epstein-Barr Virus

Six cell lines established from five patients with adult T-cellleukemia (ATL) were studied by electron microscopy. From onepatient two cell lines were established, an interleukin 2-dependentline and a nondependent line. The interleukin 2-dependent T-cellline had only ATL virus (ATLV) particles. The interleukin 2-nondependentB-cell line had both ATLV particles and Epstein-Barr virus (EBV)particles. In two other B-cell lines and one undetermined cellline, both ATLV particles and EBV particies were seen. In oneB-cell line only a few EBV particles were seen. These findingssuggest that (I) interleukin 2 is necessary for the growth ofleukemic T-cells from ATL tissue samples, and (2) ATLV can infectnot only T-cells but also B-cells.     

Perinephric angiomyolipoma: A unique development pattern surrounding the kidney

We report a case of a 31-year-old man with extrarenal angiomyolipoma of the perinephric space. He presented with asymptomatic macrohematuria. Computed tomography of the abdomen revealed a large perinephric mass which was separated from the right kidney and its unique growth appeared to have surrounded the kidney. Extrarenal angiomyolipomas of the perinephric fat are rare and they should be considered in the differential diagnosis of a retroperitoneal mass where asymptomatic macrohematuria was presented at the onset.     

Continuous Intravenous Administration of l-(2-Tetrahydrofuryl)-5-Fluorouracil [FT] by Intravenous Hyperalimentation (IVH) -- Stability of FT in IVH Solution and Tumor Levels of 5-Fluorouracil (5-FU) --

The continuous intravenous administration of l-(2-tetrahydrofuryl)-5-fluorouracil(FT) to colorectal cancer patients was studied in regard tothe stability of FT in intravenous hyperalimentation (IVH) solutionsand tumor levels of 5-fluorouracil (5-FU). FT was very compatiblewith IVH solutions, because the decomposition of FT in IVH solutionwas very low, 3%. High levels of 5-FU, which is an active metaboliteof FT, were obtained in the tumors, averaging 0.369 mcg/g. Theratios of 5-FU levels in the tumor to those in serum and normaltissues were 13.6 and 3.7. respectively. The difference in 5-FUlevels between normal tissues and the tumors was statisticallysignificant (P<0.01). Therefore, continuous intravenous administrationof FT should be widely used to treat patients with colorectalcancer, as the method of administration of antitumor agents.     

Prolapse of Foley Catheter Gastrostomy Tube Causing Obstructive Jaundice

A patient with Foley catheter tube gastrostomy was seen with vomiting and jaundice resulting from the prolapse of the tube into the jejunum. Repositioning of the catheter resulted in complete resolution of symptoms. Migration of the inflated balloon of a Foley gastrostomy tube, causing high intestinal obstruction and gastrointestinal bleeding, has been reported. Obstructive jaundice is another rare but reversible complication.     

Oil-Depot Type Bleomycin in the Treatment of Malignant Lymphoma in Comparison with Regular Bleomycin

Oil-depot type bleomycin was originally intended to take advantageof not only concentration-dependent action, but also the time-dependentaction of bleomycin to obtain more efficient tumor cell kill.In this study, the effects of oil-depot type bleomycin and regularbleomycin on 81 patients with malignant lymphoma were compared.Both oil-depot type bleomycin and regular bleomycin were equallyeffective against Hodgkin's disease, with a complete remissionrate of 60% (6/10) and 54.5% (6/11), respectively. Non-Hodgkin's lymphoma in advanced stages responded better tooil-depot type bleomycin [complete remission (CR); 35.2% (6/17)]than to regular bleomycin [CR: 10.5% (2/19)]. In addition, thepatients were more responsive to smaller doses of oil-depottype bleomycin than regular bleomycin. Eleven out of 12 (91.6%)patients who responded to oil-depot type bleomycin, went intocomplete remission before receiving 45 mg in total dosage ofbleomycin, while five out of 10 (50%) patients who respondedto regular bleomycin reached complete remission after 60 mgin total dosage was administered. The toxic manifestations of oil-depot type bleomycin were almostthe same in quality and quantity as regular bleomycin. However,the average total dose of oil-depot type bleomycin used wasalmost half of that of regular bleomycin. ^* Present address: Cancer Chemotherapy Center, Cancer ResearchInstitute, Tokyo, Japan. ^** Present address: National Nagoya Hospital, Nagoya, Japan.     

Prognostic Factors and Therapeutic Results in Multiple Myeloma

Prognostic factors in 68 consecutive patients with myeloma treatedat the National Cancer Center Hospital from 1962 to 1984 wereanalyzed. Median survival time from onset was 100 months forstage I, 72 months for stage II, and 26 months for stage IIIof the Durie and Salmon's clinical staging system. It was 55months in patients with normal renal function and 18 monthsin those with abnormal renal function. All early deaths occurredin patients with stage III disease. Hemoglobin level, bone lyticlegions and presence of Bence Jones protein were also significantprognostic factors. On the other hand, heavy chain as well aslight chain subtypes of monoclonal immunoglobulin (M-component)and M-component production rate did not influence the survivalof myeloma patients. The analysis of chemotherapeutic responsesand survival curves according to the chemotherapy used in thisstudy (alkylating agent vs Vinca-alkaloid plus alkylating agent)did not disclose any significant difference between the twogroups. The overall response rate was 67%. The survival timefrom the initial chemotherapy of responding patients was significantlylonger than that of nonresponders.     

Myxoma of the kidney

A 62-year-old man had a right renal mass incidentally diagnosed by ultrasonography. Magnetic resonance imaging revealed a well-defined right renal mass with homogenous low-signal intensity on the T(1)-weighted pulse sequence and heterogeneous high-signal intensity on the T(2)-weighted pulse sequence. A right nephrectomy was performed. The histological examination showed a myxoma, which is a very uncommon neoplasm in the kidney. Eight cases have been reported previously.     

Cyclocytidine-A Phase I Study

Cyclocytidine (2, 2'-0-cyclocytidine) is a synthetic Ara C analogwhich is not deaminated by cytidinc deaminase. Excellent antitumoreffects of this compound against L1210 and other experimentaltumors have been reported recently. Two-to-six milligrams per kilogram weight of cyclocytidine,was injected into 10 patients mainly with hematological tumors. Acute toxic symptoms by cyclocytidine were remarkably less thanthat by Ara C. Peripheral blood cell counts dropped moderatelyand megaloblastosis was detected in all specimens collectedduring the cyclocytidine treatment. No significant biochemicaland biological changes were found. Good partial remission wasobserved in 2 cases of acute leukemia.